| 1 |
Redondo MC, Arbo MD, Grindlinger J, et al. Attribut-able mortality of bacteremia associated with the Bacteroides fragilis group[J]. Clin Infect Dis, 1995, 20 (6): 1492-1496.
|
| 2 |
Brook I. Spectrum and treatment of anaerobic infections[J]. J Infect Chemother, 2016, 22 (1): 1-13.
|
| 3 |
Coltella L, Mancinelli L, Onori M, et al. Advancement in the routine identification of anaerobic bacteria by MALDI-TOF mass spectrometry[J]. Eur J Clin Microbiol Infect Dis, 2013, 32 (9): 1183-1192.
|
| 4 |
Crombleholme WR, Ohm-Smith M, Robbie MO, et al. Ampicillin/sulbactam versus metronidazole-gentamicin in the treatment of soft tissue pelvic infections[J]. Am J Obstet Gynecol, 1987, 156 (2): 507-512.
|
| 5 |
Falagas ME, Siakavellas E. Bacteroides, Prevotella, and Porphyromonas species: a review of antibiotic resistance and therapeutic options[J]. Int J Antimicrob Agents, 2000, 15 (1): 1-9.
|
| 6 |
Brook I. The role of anaerobic bacteria in bacteremia[J]. Anaerobe, 2010, 16 (3): 183-189.
|
| 7 |
Duerden BI, Eley A, Goodwin L, et al. A comparison of Bacteroides ureolyticus isolates from different clinical sources[J]. J Med Microbiol, 1989, 29 (1): 63-73.
|
| 8 |
Nguyen MH, Yu VL, Morris AJ, et al. Antimicrobial resistance and clinical outcome of bacteroides bacteremia: findings of a multicenter prospective observational trial[J]. Clin Infect Dis, 2000, 30 (6): 870-876.
|
| 9 |
Smith JM, Avdic E, Tamma PD, et al. Risk factors for resistance to β-lactam/β-lactamase inhibitors and ertapenem in Bacteroides bacteremia[J]. Antimicrob Agents Chemother, 2015, 59 (8): 5049-5051.
|
| 10 |
Blandino G, Milazzo I, Fazio D, et al. Antimicrobial susceptibility and beta-lactamase production of anaerobic and aerobic bacteria isolated from pus specimens from orofacial infections[J]. J Chemother, 2007, 19 (5): 495-499.
|
| 11 |
Lassmann B, Gustafson DR, Wood CM, et al. Reemergence of anaerobic bacteremia[J]. Clin Infect Dis, 2007, 44 (7): 895-900.
|
| 12 |
Brook I. Clinical review: bacteremia caused by anaerobic bacteria in children[J]. Crit Care, 2002, 6 (3): 205-211.
|
| 13 |
Gradison M. Pelvic inflammatory disease[J]. Am Fam Physician, 2012, 85 (8): 791-796.
|
| 14 |
Jeverica S, Kolenc U, Mueller-Premru M, et al. Evaluation of the routine antimicrobial susceptibility testing results of clinically significant anaerobic bacteria in a Slovenian tertiary-care hospital in 2015[J]. Anaerobe, 2017 (47): 64-69.
|
| 15 |
丁利，吕苏明，张天友，等. 42例阻塞性睡眠呼吸暂停综合症患者高压氧治疗前后的对比研究[J/CD]. 中华危重症医学杂志（电子版），2015，8(6): 371-373.
|
| 16 |
Mathieu D, Marroni A, Kot J. Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment[J]. Diving Hyperb Med, 2017, 47 (1): 24-32.
|
| 17 |
Korhonen K. Hyperbaric oxygen therapy in acute necrotizing infections. With a special reference to the effects on tissue gas tensions[J]. Ann Chir Gynaecol, 2000, 89 (Suppl 214): 7-36.
|
| 18 |
Zanon V, Rossi L, Castellani E, et al. Oxybiotest project: microorganisms under pressure. Hyperbaric oxygen (HBO) and simple pressure interaction on selected bacteria[J]. Med Gas Res, 2012, 2 (1): 24.
|
| 19 |
Lima FL, Joazeiro PP, Lancellotti M, et al. Effects of hyperbaric oxygen on Pseudomonas aeruginosa susceptibility to imipenem and macrophages[J]. Future Microbiol, 2015, 10 (2): 179-189.
|